HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Generate Biomedicines (NASDAQ: GENB) and maintained a price target of $30 for the stock.